Trevor Bossi

Trevor represents issuers, investors and investment banks across various capital markets transactions, including initial public offerings (IPOs), follow-on public offerings, private investments in public equity (PIPEs), at-the-market (ATM) offerings and debt offerings. He regularly advises domestic and foreign life sciences companies regarding US Securities and Exchange Commission periodic reporting and disclosure obligations, annual meeting and proxy-related issues, beneficial ownership reporting, securities exchange listing standards, corporate governance, and Sarbanes-Oxley Act compliance, as well as other general corporate and securities matters. Trevor has also represented companies in connection with life sciences licensing transactions, reverse mergers, tender offers and other strategic transactions.

Trevor’s company-side and underwriter-side representations include:

• VectivBio
  • $1 billion acquisition by Ironwood Pharmaceuticals pursuant to a tender offer
• Immunovant
  • $450 million PIPE
  • $492 million follow-on offering and concurrent PIPE
  • $75 million underwritten offering
  • $150 million ATM facility and public company representation
• Oculis Holding
  • $100 million underwritten offering
  • $59 million Icelandic financing and listing on Nasdaq Iceland Main Market
  • $100 million ATM facility
  • $42.5 million follow-on offering
  • $220 million reverse merger and concurrent PIPE
  • Public company representation
• Autolus Therapeutics
  • February 2024 strategic collaboration with BioNTech to advance autologous CAR-T programs and concurrent $200 million private placement of American depositary shares (ADSs) to BioNTech
  • $350 million registered direct offering
  • $150 million follow-on offering
  • Public company representation
• Tenet Medicines
  • $210 million acquisition by Eliem Therapeutics
• Tectonic Therapeutic
  • $185 million private placement
• Rigetti Computing
  • $100 million registered direct offering
• Immunocore Holdings
  • $350 million convertible notes offering
• Valneva
  • 61-million-euro European accelerated bookbuild and US PIPE
  • $99 million global offering
  • $75 million ATM facility
  • Public company representation
• Nanobiotix
  • Represented the underwriters of its $54 million global offering
• Faron Pharmaceuticals
  • $10 million US private placement
  • 30-million-euro European accelerated bookbuild and US PIPE
  • 12-million-euro European accelerated bookbuild and US PIPE
  • 8-million-euro European accelerated bookbuild and US PIPE
• Repare Therapeutics
  • $88 million follow-on offering
  • $125 million and $100 million ATM facilities
  • Public company representation
• Molecular Partners
  • $20 million underwritten offering
  • $100 ATM facility
  • Public company representation
• Addex Therapeutics
  • April 2024 sale of discovery platform and portfolio of preclinical programs
  • March 2023 registered direct offering of ADSs and warrants
  • July 2022 registered direct offering of ADSs and warrants
  • Public company representation
• Nykode Therapeutics
  • 505-million-Norwegian-krone private placement
• Nextdoor
  • $674 million de-SPAC (special purpose acquisition company)*
• Faraday Future
  • $3.4 billion de-SPAC*
• Romeo Power
  • $1.33 billion de-SPAC*
• Khosla Ventures
  • $300 million, $400 million and $500 million SPAC IPOs*

* Representation handled prior to joining Cooley